With shares of Exact Sciences Corporation (NASDAQ:EXAS) up more than 55% in the last year and up nearly 60% YTD, executives of the company recently moved to book profits in their stock options. The insiders who recently sold shares in the company to unlock profits included CEO Kevin T Conroy.

As per a regulatory filing, Conroy sold 600,000 shares in Exact Sciences at an average price of $17.46 apiece. As such, the transaction that was completed on November 15 yielded $10.5 million in proceeds for the executive.

Another executive selling Exact Sciences shares was Graham Peter Lidgard, the company’s Chief Science Officer. Lidgard sold 311,112 shares at the same average price of $17.46 as the CEO.

Exact Sciences’ COO, Maneesh Arora, also took the cue, offloading 562,932 shares at an average price of $17.46 as well. Lidgard and Arora did their transaction on the same day as CEO Conroy.

Executive promotion

The sale of shares by executives in Exact Sciences comes on the heels of a recent promotion of Jeff Elliott to chief financial officer (CFO). Until his new appointment, Elliott was VP of Business Development and Strategy at Exact Sciences, having joined the company in June this year from equity research firm Robert W. Baird.

Exact Sciences CEO Conroy said the company is looking to benefit from the knowledge and experience in financial strategy and diagnostics sector that Elliott is bringing to the table. The appointment of Elliott to the new role also came at a time when Exact Sciences has been touting strong demand for its Cologuard product. Exact Sciences hopes Elliott can help it capitalize on the opportunities ahead in colon cancer treatment market.

3Q16 earnings

Exact Sciences logged EPS loss of $-0.36 for 3Q16, but still beat the consensus estimate that called for EPS loss of $0.42. Revenue of $28.12 million rose 123% and exceeded the consensus estimate by more than $2.8 million.